Vuity eye drops cost price 2026?

Vuity (lifitegrast ophthalmic solution) is the branded eye‑drop treatment that FDA‑approved for moderate‑to‑severe dry‑eye disease in 2019. It’s a prescription drug, so the price you see on the shelf is the list price (also called the “average wholesale price” or “average selling price”), not the manufacturing cost. The “cost price” that the manufacturer actually pays to make the drug is confidential and isn’t publicly disclosed.

Current (2024) retail picture

Notes:

• The price is per 30 mL bottle. A typical patient uses a few drops per eye once or twice a day, so a bottle can last roughly 2–3 months.
• Some insurers have a “preferred” drug tier that can cut the patient’s out‑of‑pocket cost to $5–$15 per bottle. Others may require a higher copay or a prior‑authorization step.

What the manufacturer pays (the “cost price”)

The actual manufacturing cost for a small, single‑use ophthalmic solution is a fraction of the list price. Rough estimates from industry analysts and pharmaceutical economics studies suggest:

• Direct material cost (active drug, excipients, containers, labeling): $5–$10 per bottle.
• Labor, quality control, and regulatory compliance: $3–$5.
• Distribution and marketing (shipping, pharmacy margins, brand building): $20–$30.
• Profit margin (Pharma companies often target 30–40 % net margin on a drug of this class).

So the total cost to the manufacturer is likely $30–$50 per bottle – only a tiny fraction of the $300–$400 retail price. That gap is made up by pharmacy markup, insurance contracts, and the company’s overall pricing strategy.

What could happen by 2026?

1. Inflation and generic competition

   • If a generic version of lifitegrast is approved (currently in the pipeline), the list price could drop dramatically—often to $80–$120 per bottle.
   • Even without a generic, overall medical‑drug inflation in the U.S. is projected at ~3–5 % annually, so a 2026 list price of $320–$450 is plausible.

2. Insurance formulary changes

   • Payers may negotiate tighter rebates or require step‑in therapy, which can lower the net price paid by the insurer and potentially reduce copays for patients.

3. Manufacturer price adjustments

   • Roche (the company that markets Vuity) may adjust the list price to keep the drug competitive and maintain market share, especially if new therapies enter the dry‑eye space.

4. Patient assistance programs

   • Roche offers a “Vuity Assistance” program that can cover the cost for eligible patients, sometimes bringing the out‑of‑pocket cost to zero or a few dollars.

Bottom line

• Retail list price (2024–2026 estimate): $300–$450 per bottle.
• Actual manufacturing cost (estimate): $30–$50 per bottle.
• Patient cost: varies widely based on insurance; could be $5–$15 per bottle if the drug is on a preferred tier, or up to $200+ if the patient pays fully out‑of‑pocket.

If you’re looking for the exact price at a specific pharmacy or have a particular insurance plan, the best next step is to check the pharmacy’s website or call your insurer’s pharmacy benefits manager (PBM). Drug‑pricing databases like the Red Book or the FDA’s “Drug Pricing” portal can also give you the most recent wholesale and average selling prices.